The Nationwide Institute of Allergy and Infectious Illnesses (NIAID), a part of the Nationwide Institutes of Well being, just lately awarded greater than $12 million to a few establishments for the event of antiviral therapies to deal with illnesses brought on by viruses with pandemic potential. NIAID might award roughly $61.5 million complete over 5 years if all contract choices are exercised. The brand new product growth contracts are a part of the Antiviral Program for Pandemics (APP), which goals to speed up the invention, growth and manufacturing of antiviral medicines.
Antivirals are therapies that combat viral infections by performing immediately in opposition to the virus. Different kinds of therapies, not the main focus of this program, harness the physique’s immune system to combat an infection. The brand new contracts will help the event of promising antiviral candidates from late-stage preclinical research by way of investigational new drug application-enabling actions and medical testing.
Alongside the brand new product growth contracts, NIAID already helps 9 Antiviral Drug Discovery (AViDD) Facilities for Pathogens of Pandemic Concern. The AViDD Facilities conduct analysis on the early-stage identification and validation of novel viral targets and identification and early-stage characterization of antiviral drug candidates.
The brand new product growth contracts embrace:
Optimization of Broad-Spectrum Filovirus Inhibitors that Goal Viral Glycoprotein
Principal investigator: Terry Bowlin, Ph.D.
Institute: Microbiotix, Inc., Worcester, Massachusetts
Base funding quantity: $2,069,416
NIAID contract: 75N93023C00001
Growth of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungunya Virus An infection and Illness
Principal investigator: Daniel Streblow, Ph.D.
Institute: Oregon Well being and Science College, Portland
Base funding quantity: $4,696,452
NIAID contract: 75N93023C00002
Growth of an Orally Accessible Antiviral Drug for Yellow Fever
Principal investigator: Jinhong Chang, M.D., Ph.D.
Institute: Baruch S. Blumberg Institute, Doylestown, Pennsylvania
Base funding quantity: $5,493,876
NIAID contract: 75N93023C00003
For extra details about the APP, please go to: https://www.niaid.nih.gov/research/antivirals.